2,2-Dimethyl-capronsaeure-methylester | 813-69-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-Dimethyl-capronsaeure-methylester
• 英文别名: methyl 2,2-dimethylhexanoate；2,2-dimethyl-hexanoic acid methyl ester
• CAS: 813-69-4
• 化学式: C₉H₁₈O₂
• mdl: MFCD02684338
• 分子量: 158.241
• InChiKey: PWIVQUPZVUNZKX-UHFFFAOYSA-N

物化性质

• 沸点：
  64 °C(Press: 18 Torr)
• 密度：
  0.8762 g/cm3
• 保留指数：
  936

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-Dimethyl-capronsaeure-methylester 在 草酰氯 、 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 1.5h， 生成 2,2-dimethylhexanoyl chloride
  参考文献：
  名称：

  Palladium-Catalyzed β-Mesylation of Simple Amide via Primary sp³ C–H Activation

  摘要：

  A beta-mesylation of primary sp(3) C-H bonds from simple amides with methanesulfonic anhydride; (Ms2O) has been established successfully A 80 degrees C in a Pd(OAc)(2) (catalyst)/K2S2O8 (oxidant)CF3CH2OH (solvent) system. These amide substrates involve N-monosubstituted linear,, branch, or cyclic alkanes, and electron-deficient benzyl compounds. The beta-mesylated amide products can be converted easily to beta-fluoroamideS or beta-lactams through inter- or intramolecular S(N)2 processes.

  DOI：

  10.1021/acs.orglett.7b00536
• 作为产物：
  描述：

  异丁酸甲酯 生成 2,2-Dimethyl-capronsaeure-methylester
  参考文献：
  名称：

  MARTIN, I.;ANVELT, J.;VALIMAE, T.;PEHK, T. LILLE U., SYNTH. COMMUN., 20,(1990) N7, C. 2597-2605

  摘要：

  DOI：

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160289229A1

  公开（公告）日：2016-10-06

  The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

  本公开涉及调节类似受体调节剂化合物，例如二氨基吡啶并[3,2 D]嘧啶化合物和药物组合物，其中调节类似受体（例如TLR-8），以及制备和使用它们的方法。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 derivatives
  申请人：Toray Industries, Inc.

  公开号：US04775692A1

  公开（公告）日：1988-10-04

  Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, X, R.sub.2 and R.sub.3 are as defined herein.

  本文披露了一种展现出优异体内持续时间和活性的新型前列腺素I.sub.2（PGI.sub.2）衍生物，所述衍生物由以下一般式表示：##STR1##其中R.sub.1、X、R.sub.2和R.sub.3如本文所定义。
• TRPV1 agonist compounds and methods for making and using the same
  申请人：Jamieson Curtis Gene

  公开号：US20060240097A1

  公开（公告）日：2006-10-26

  Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.

  这里描述了TRPV1激动剂化合物及其合成和使用方法。除了具体识别的化合物外，还描述了辣椒素前药、双子星二聚体和相互前药。TRPV1激动剂化合物的配方可以是液体、片剂、胶囊、凝胶、乳霜、乳状液、贴片等形式。还提供了使用所述化合物、组合物或前药治疗医疗状况的方法。